IP Library › Granted Patent US 12,698,513
Granted Patent B2
US 12,698,513 · App. 17/428,880 · Granted Aug 4, 2026

CRISPR compositions and methods for promoting gene editing of ribosomal protein S19 (RPS19) gene

Inventors: David Baram (Tel Aviv, IL); Lior Izhar (Tel Aviv, IL); Asael Herman (Ness-Ziona, IL); Rafi Emmanuel (Ramla, IL); Michal Golan Mashiach (Ness-Ziona, IL); Joseph Georgeson (Rehovot, IL)
Assignee: EmendoBio Inc.
C12N15/907A61K31/7105A61K35/28A61P7/06C12N5/0647C12N9/22C12N15/11C12N2310/20C12N2501/125C12N2501/22C12N2501/2303C12N2510/00C12N2800/80
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,698,513
App. No.
17/428,880
Granted
Aug 4, 2026
Kind
B2
Abstract

Isolated guide RNA (gRNA) molecules comprising CRISPR (crRNA) molecules that target the 19:41869823_T_C mutation of a Ribosomal Protein S19 (RPS19) allele.

Claims (10)

1 . An isolated guide RNA molecule (gRNA) that targets a mutant Ribosomal Protein S19 (RPS19) allele, wherein the gRNA comprises a CRISPR RNA (crRNA) molecule comprising the nucleic acid sequence set forth in SEQ ID NOs: 6269, 6357, 6449, 6315, 6405, or 6388.

2 . The isolated gRNA of claim 1 , wherein the crRNA molecule comprises the nucleic acid sequence set forth in SEQ ID NO: 6269.

3 . An isolated gRNA that targets a mutant RPS19 allele, wherein the gRNA comprises a crRNA molecule consisting of the nucleic acid sequence set forth in SEQ ID NO: 6269, 6357, 6449, 6315, 6405, or 6388.

4 . The isolated gRNA of claim 3 , wherein the crRNA molecule consists of the nucleic acid sequence set forth in SEQ ID NO: 6269.

5 . The isolated gRNA of claim 3 , wherein the crRNA molecule consists of the nucleic acid sequence set forth in SEQ ID NO: 6357.

6 . The isolated gRNA of claim 3 , wherein the crRNA molecule consists of the nucleic acid sequence set forth in SEQ ID NO: 6449.

7 . The isolated gRNA of claim 3 , wherein the crRNA molecule consists of the nucleic acid sequence set forth in SEQ ID NO: 6315.

8 . The isolated gRNA of claim 3 , wherein the crRNA molecule consists of the nucleic acid sequence set forth in SEQ ID NO: 6405.

9 . The isolated gRNA of claim 3 , wherein the gRNA comprises a crRNA consisting of the nucleic acid sequence set forth in SEQ ID NO: 6388.

10 . A composition comprising the isolated guide RNA molecule of claim 1 , a donor DNA template for homology directed repair (HDR), alteration, or replacement of a target sequence of the RPS19 allele, one or more CRISPR nucleases or sequences encoding the one or more CRISPR nucleases, and one or more tracrRNA molecules or sequences encoding the one or more tracrRNA molecules.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 6, 2021
From: BARAM, DAVID; IZHAR, LIOR; HERMAN, ASAEL; EMMANUEL, RAFI; GOLAN MASHIACH, MICHAL; GEORGESON, JOSEPH
To: EMENDOBIO INC.
Reel/Frame 057108/0494 →
Continuity (3)
Provisional Application 62861183 · Jun 13, 2019
Provisional Application 62801603 · Feb 5, 2019
Related Publication 20220098621A1 · Mar 31, 2022
References Cited (17)
US 20140170753A1 · Zhang · 2014 [cited by examiner]
WO WO2017191187A2 · 2017 [cited by examiner]
Clancy, S. (2008) RNA Functions. Nature Education 1(1):102 (Year: 2008). [cited by examiner]
Bernat et al. RNA Structures as Mediators of Neurological Diseases and as Drug Targets. Neuron. Jul. 1, 2015;87(1):28-46. (Year: 2015). [cited by examiner]
Nowak et al. Guide RNA engineering for versatile Cas9 functionality. Nucleic Acids Res. Nov. 16, 2016;44(20):9555-9564. Epub Oct. 12, 2016. (Year: 2016). [cited by examiner]
International Preliminary Report on Patentability issued Aug. 10, 2021 including Written Opinion of the International Searching Authority issued Jul. 5, 2020, in connection with PCT International Application No. PCT/US2… [cited by applicant]
International Search Report issued Jul. 17, 2020 in connection with PCT International Application No. PCT/US2020/016643. [cited by applicant]
Written Opinion (form PCT/ISA/237) issued Jul. 17, 2020 in connection with PCT International Application No. PCT/US2020/016643. [cited by applicant]
Aguirre, A. J. “Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting.” Cancer Discovery, vol. 6, No. 8, Jun. 3, 2016, pp. 914-929 and Supplementary data. [cited by applicant]
Anonymous: “Diamond Blackfan Anemia Foundation Hosts 14th DBA International Consensus Conference.” 2016. [cited by applicant]
Anonymous: “NM_001022. 3 (RPS19):c.—339T>C.” ClinVar Database, Jun. 14, 2016. [cited by applicant]
Aspesi, A. et al. “Emerging Therapeutic Approaches for Diamond Blackfan Anemia.” Current Gene Therapy, vol. 18, No. 6, Dec. 12, 2018, pp. 327-335. [cited by applicant]
Campagnoli, M. F. “RPS19 Mutations in Patients With Diamond-Blackfan Anemia.” Human Mutation, vol. 29, No. 7, Apr. 15, 2008, pp. 911-920. [cited by applicant]
Da Costa, L. “Molecular approaches to diagnose Diamond-Blackfan anemia: The EuroDBA experience.” European Journal of Medical Genetics, vol. 61, No. 11, Oct. 26, 2017, pp. 664-673. [cited by applicant]
Doench, J. G. et al. “Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9.” Nature Biotechnology, vol. 34, No. 2, Jan. 18, 2016, pp. 184-191 and Tables S21-S22. [cited by applicant]
Westin, E. et al. “Correction of Diamond-Blackfan Induced Pluripotent Stem Cells via CRISPR.” Abstracts of “Molecules for Minions: Southeastern Pediatric Research Innovation Conference,” Jun. 22, 2016, Atlanta, p. 17. [cited by applicant]
Westin, E. et al. “Crispr Modification of Induced Pluripotent StemDerived from Diamond-Blackfan Anemia Fibroblasts.” Blood, vol. 124, No. 21, Dec. 6, 2014. [cited by applicant]